Back

Arletta appoints Jeannette Jager-van Dijk CEO for 2026 U.S. Phase 2 strategy

Verifying
  • Arletta appointed Jeannette Jager-van Dijk Chief Executive Officer effective September 1, 2026.
  • FDA supported core elements of the proposed U.S. Phase 2 MONARCH design.
  • Jager-van Dijk previously led Livial development, registration and marketing responsibilities at Organon.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.